Gilead Sciences Inc
NASDAQ: GILD
$88.40
-$3.71 (-4.0%)
Closing Price on November 15, 2024
GILD Articles
The recent violent sell-off has unnerved investors and given the bears the floor for the first time in a while. However, there are some positive signs that job growth and workforce participation are...
Published:
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at Credit Suisse.
Published:
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and...
Published:
Jon OggMost investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs...
Published:
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated Outperform...
Published:
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of...
Published:
After retreating from many leading biotech and emerging pharmaceutical stocks in the previous two periods, short sellers returned in early March, especially in Celgene, Medivation and Pharmacyclics.
Published:
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
Published:
Biotech and emerging pharmaceutical stocks continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical and Medivation.
Published:
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some...
Published:
Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top health care names to buy now...
Published:
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin...
Published:
Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added to the Piper Jaffray Model Portfolio.
Published:
In a new research report, the analysts at Deutsche Bank unveil their "what to buy now ?" list for large cap stocks. We picked a top names from each sector listed in the report, focusing on the names...
Published:
With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good chance for investors to get timely updates on the top stocks and their...
Published: